|Target||Interferon α/β receptor|
|Chemical and physical data|
|Molar mass||145.12 kg/mol|
Anifrolumab is a monoclonal antibody designed for the treatment of systemic lupus erythematosus.
The most common adverse effect in the study was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Anifrolumab, American Medical Association.
- H. Spreitzer (29 August 2016). "Neue Wirkstoffe - Anifrolumab". Österreichische Apothekerzeitung (in German) (18/2016).